does pfizer make glp 1 drugs Structure Raises $300M as Oral GLP-1 Drug's Data Keep Up With Pfizer, Eli Lilly Medicare will negotiate Novo's GLP-1

Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function

This article reviews the glucagon-like peptide 1 (GLP-1) agonistbased therapies as a new class of antidiabetic and their potential effects beyond glucose control that may ultimately impact cardiovascular disease

Cureus 17(7)

Your doctor might suggest Ozempic alternatives that are more affordable or have BCBS coverage

As previously mentioned, patients with T2D on incretin-based therapies showed significant weight loss and improved glycemic control with little experience of hypoglycemia (47)

Less common side effects included dyspepsia, fatigue, eructation (belching), hair loss, gastroesophageal reflux, dizziness, and gastritis (Table 2)